Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure

Heart

Volumn 105, Issue 4, 2019, Pages 307-314

  Ferreira, João Pedro ^a,b   Rossignol, Patrick ^a   Pizard, Anne ^a   Machu, Jean Loup ^a   Collier, Timothy ^c   Girerd, Nicolas ^a   Huby, Anne Cécile ^a   Gonzalez, Arantxa ^d,e   Diez, Javier ^d,e,f   López, Begoña ^e   Sattar, Naveed ^g   Cleland, John G ^h,i   Sever, Peter S ^j   Zannad, Faiez ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b UNIVERSITY OF PORTO   (Portugal)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d Recinto de Complejo Hospitalario de Navarra   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f UNIVERSITY CLINIC OF NAVARRA   (Spain)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

heart failure; hypertension

Indexed keywords

BIOLOGICAL MARKER; CARBOXY TERMINAL PROPEPTIDE OF PROCOLLAGEN TYPE 1; CARBOXY TERMINAL TELOPEPTIDE OF COLLAGEN TYPE 1; COLLAGEN; INTERSTITIAL COLLAGENASE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SPIRONOLACTONE; UNCLASSIFIED DRUG; MINERALOCORTICOID ANTAGONIST; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I CARBOXY TERMINAL PEPTIDE; PROCOLLAGEN TYPE III-N-TERMINAL PEPTIDE;

ADD ON THERAPY; ADULT; AGE; AGED; ARTICLE; COLLAGEN METABOLISM; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESISTANT HYPERTENSION; TREATMENT DURATION; BIOAVAILABILITY; BIOSYNTHESIS; BLOOD; BLOOD PRESSURE; COMPLICATION; DRUG MONITORING; DRUG RESISTANCE; HEART FAILURE; HYPERTENSION; METABOLISM; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL;

AGED; BIOLOGICAL AVAILABILITY; BIOMARKERS; BLOOD PRESSURE; COLLAGEN; DRUG MONITORING; DRUG RESISTANCE; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; OUTCOME ASSESSMENT, HEALTH CARE; PEPTIDE FRAGMENTS; PROCOLLAGEN; SPIRONOLACTONE;

EID: 85052475176     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2018-313182     Document Type: Article

References (31)

1. Lee DS, Gona P, Albano I, et al. A systematic assessment of causes of death after heart failure onset in the community: impact of age at death, time period, and left ventricular systolic dysfunction. Circ Heart Fail 2011;4:36-43.
2. Jacobs L, Efremov L, Ferreira JP, et al. Risk for incident heart failure: a subject-level meta-analysis from the Heart OMics in AGE ing (HOMAGE ) Study. J Am Heart Assoc 2017;6:e005231.
3. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press 2014;23:3-16.
4. Messerli FH, Rimoldi SF, Bangalore S. The transition from hypertension to heart failure: contemporary update. JACC Heart Fail 2017;5:543-51.
5. Wright JT, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103-16.
6. López B, Querejeta R, González A, et al. Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase. Hypertension 2012;60:677-83.
7. López B, Ravassa S, González A, et al. Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure. J Am Coll Cardiol 2016;67:251-60.
8. Heymans S, González A, Pizard A, et al. Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. Eur J Heart Fail 2015;17:764-71.
9. Ferreira JP, Machu JL, Girerd N, et al. Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. ESC Heart Fail 2018;5.
10. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATH WAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386:2059-68.
11. Ferreira JP, Duarte K, Montalescot G, et al. Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study. Clin Res Cardiol 2018;107.
12. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000;102:2700-6.
13. Iraqi W, Rossignol P, Angioi M, et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 2009;119:2471-9.
14. Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, et al. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. JACC Cardiovasc Imaging 2011;4:1239-49.
15. Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, et al. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade. Heart 2013;99:320-6.
16. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839-45.
17. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
18. Gyöngyösi M, Winkler J, Ramos I, et al. Myocardial fibrosis: biomedical research from bench to bedside. Eur J Heart Fail 2017;19:177-91.
19. Eschalier R, Fertin M, Fay R, et al. Extracellular matrix turnover biomarkers predict long-term left ventricular remodeling after myocardial infarction: insights from the REVE-2 study. Circ Heart Fail 2013;6:1199-205.
20. Condorelli G, Jotti GS, Pagiatakis C. Fibroblast senescence as a therapeutic target of myocardial fibrosis: beyond spironolactone? J Am Coll Cardiol 2016;67:2029-31.
21. Bielecka-Dabrowa A, Gluba-Brzózka A, Michalska-Kasiczak M, et al. The multibiomarker approach for heart failure in patients with hypertension. Int J Mol Sci 2015;16:10715-33.
22. López B, González A, Ravassa S, et al. Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal. J Am Coll Cardiol 2015;65:2449-56.
23. Klappacher G, Franzen P, Haab D, et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 1995;75:913-8.
24. Uusimaa P, Risteli J, Niemelä M, et al. Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency. Circulation 1997;96:2565-72.
25. Izawa H, Murohara T, Nagata K, et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 2005;112:2940-5.
26. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003;107:2559-65.
27. Montalescot G, Pitt B, Lopez de Sa E, et al. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. Eur Heart J 2014;35:2295-302.
28. López B, Querejeta R, González A, et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004;43:2028-35.
29. Querejeta R, Varo N, López B, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000;101:1729-35.
30. Jellis CL, Sacre JW, Wright J, et al. Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy. Eur Heart J Cardiovasc Imaging 2014;15:776-86.
31. Jacobs L, Thijs L, Jin Y, et al. Heart 'omics' in AGE ing (HOMAGE ): design, research objectives and characteristics of the common database. J Biomed Res 2014;28:349-59.